I am a urologic surgeon whose focus is on the care of patients with urologic malignancies, especially kidney tumors. Because the treatment of kidney cancer is complex and continues to evolve, I work closely with colleagues in medical oncology, radiology, and pathology to deliver the most up-to-date, multidisciplinary care. Sometimes multiple treatments can exist for these conditions, and it’s essential that patients have a thorough knowledge of their options. If surgery is the recommended treatment, my team and I will answer all the questions patients may have leading up to and recovering from surgery. I utilize open, endoscopic, and minimally invasive (robotic) treatments and tailor the approach based on each patient’s unique circumstances.
I believe that significant advances in cancer care will be made through the analysis of vast amounts of data being generated from genetic sequencing. Therefore, my laboratory research focuses on understanding the mechanisms of kidney cancer initiation and progression while utilizing these genomic approaches. For this, I work closely with computational and molecular biologists. The goals of these collaborations are to translate the discoveries we make in the lab into clinically meaningful improvements for my patients.
I have lectured and published extensively on the genomic underpinnings of kidney cancer and identified several mutations that predict more aggressive disease. For this and other work, I have received awards from the American Society of Clinical Oncology, Society of Urologic Oncology and the Kidney Cancer Association. Ultimately the goals of my clinical work and research are the same – to individualize patient care.
- Clinical Expertise: Urologic Cancers; Kidney Cancer; Open and Minimally Invasive Surgery
- Languages Spoken: English; Hebrew
- Education: MD, Albert Einstein College of Medicine
- Residencies: Montefiore Medical Center; Albert Einstein College of Medicine
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Urology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more